Update on antibody–drug conjugates: where are we now, & where are we going?

Immuno-Oncology Insights 2022; 3(5), 195 –198

DOI: 10.18609/ioi.2022.022

Published: 16 April 2022
Viewpoint
Fernanda Arnaldez

“Antibodydrug conjugates are an expanding and promising market segment, as they offer a canvas for innovation almost in any single aspect of their design and development.”